This study validates a genetic blood "signature" that assists clinicians in identifying patients with Friedreich's Ataxia (FRDA) who are developing cardiac or metabolic complications.
The research explores the use of microRNAs as non-invasive biomarkers, aiming to identify blood indicators more accurate than current standards, such as troponin, for diagnosing hypertrophic cardiomyopathy and diabetes.
Notably, the combination of two specific microRNAs (miR-323a-3p and miR-625-3p) demonstrated a superior ability to classify and predict HCM, outperforming traditional protein biomarkers.
Furthermore, the study confirmed that other microRNAs, such as miR-128-3p and miR-130b-5p, are significantly elevated in patients suffering from both ataxia and diabetes.
